Research Analysts Set Expectations for RARE FY2024 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Wedbush lifted their FY2024 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn ($5.85) per share for the year, up from their previous estimate of ($5.96). Wedbush has a “Neutral” rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($0.80) EPS and FY2029 earnings at $3.22 EPS.

Several other equities research analysts have also commented on RARE. Piper Sandler upped their price target on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 22nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Finally, Wells Fargo & Company boosted their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $42.49 on Monday. The company has a market cap of $3.92 billion, a price-to-earnings ratio of -6.57 and a beta of 0.58. The business’s 50-day moving average is $44.50 and its two-hundred day moving average is $49.65. Ultragenyx Pharmaceutical has a fifty-two week low of $37.02 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.23) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC grew its position in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 294 shares during the last quarter. Motley Fool Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 0.3% during the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock valued at $8,005,000 after purchasing an additional 360 shares during the period. KBC Group NV grew its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 506 shares during the last quarter. M&T Bank Corp increased its stake in Ultragenyx Pharmaceutical by 8.1% in the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock worth $388,000 after buying an additional 525 shares during the period. Finally, Amalgamated Bank lifted its holdings in Ultragenyx Pharmaceutical by 13.4% during the 2nd quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 696 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 11,727 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This represents a 0.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.80% of the stock is currently owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.